Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

@article{Hayward2003AntisenseBD,
  title={Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.},
  author={Richard Laurence Hayward and Janet S. Macpherson and Jeff Cummings and Brett P. Monia and John F. Smyth and Duncan I. Jodrell},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 7},
  pages={2856-65}
}
PURPOSE To identify determinants of the effect of antisense-mediated Bcl-xl down-regulation (Bcl-xl knockdown) on the response of colorectal cancer cells to SN38, the active metabolite of irinotecan, a topoisomerase I inhibitor licensed for colorectal cancer chemotherapy. EXPERIMENTAL DESIGN Using wild-type HCT116, p53 null, Bax null, or p21/WAF1 null… CONTINUE READING